Please login to the form below

Not currently logged in
Email:
Password:

Novartis cuts price of malaria drug

Novartis has made significant price cuts to its malaria medicine, increasing access to the drug for millions of people on the African continent. The reduction in costs coincides with World Malaria Day on April 25
Novartis has made significant price cuts to its malaria medicine, increasing access to the drug for millions of people on the African continent. The reduction in costs coincides with World Malaria Day on April 25.

The price of malaria drug Coartem, which Novartis provides to the public sector on a not-for-profit basis, has been reduced by an average of 20 per cent.

By focusing investment and pushing through the expansion of is production capacity at facilities in China and the US, Novartis has increased the efficacy of Coartem manufacture. Coartem (artemether/lumefantrine) is the only fixed dose artemisinin-based combination treatment (ACT) available for treatment of malaria.

Dr Daniel Vasella, chairman and chief executive officer of Novartis, said: "We are pleased that Novartis is able to significantly reduce the price of Coartem which will further improve access to Coartem for patients in developing countries, helping save even more lives."

"The effectiveness of Coartem made it the leading ACT medicine in malaria-endemic countries," he added.

Since 2001, Novartis has supplied malaria-affected countries with more than 160 million treatments to combat the disease. According to Novartis, Coartem has yielded cure rates of 95 per cent, even in areas where cases of drug resistant malaria occur.

Between 300 and 500 million people contract malaria every year and a million will die from the disease.

23rd April 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics